Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452803 | 1.00 | ABCC4 (0.56) | ABCC4MAPTNOD1GNPATFOLH1 | |
| SCHEMBL2894648 | 0.91 | SLC6A5 (0.59) | ABCC4MAPTNOD1GNPATSLC6A5 | |
| SCHEMBL2897531 | 0.91 | SLC6A5 (0.59) | ABCC4MAPTNOD1GNPATSLC6A5 | |
| SCHEMBL7043975 | 0.88 | ALDH1A1 (0.51) | ABCC4MAPTNOD1GNPATSLC6A5 | |
| SCHEMBL5177232 | 0.88 | ALDH1A1 (0.51) | ABCC4MAPTNOD1GNPATSLC6A5 | |
| SCHEMBL27974510 | 0.87 | NOD1 (0.67) | NOD1GNPATFOLH1RIMKLANAALAD2 | |
| SCHEMBL19049826 | 0.85 | NOD1 (0.65) | NOD1GNPATFOLH1RIMKLANAALAD2 | |
| SCHEMBL19049828 | 0.85 | NOD1 (0.65) | NOD1GNPATFOLH1RIMKLANAALAD2 | |
| SCHEMBL19034801 | 0.85 | NOD1 (0.65) | NOD1GNPATFOLH1RIMKLANAALAD2 | |
| SCHEMBL13753507 | 0.85 | NOD1 (0.65) | NOD1GNPATFOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| EP-1141011-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042071-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | ABCC4 2633/4885MAPT 4750/4885NOD1 3028/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | ABCC4 3880/4885MAPT 4741/4885NOD1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.